Urology perspective on the expanding world of germline testing for prostate cancer.

Urology perspective on the expanding world of germline testing for prostate cancer. Can J Urol. 2019 Oct;26(5S2):5-6 Authors: Cookson MS Abstract The management of high-risk prostate cancer is evolving. Currently, most decisions are based on traditional factors such as tumor grade and stage. However, we are in a state of evolution. A new understanding of the value of both genetic and somatic germline testing is upon us. Perhaps even more exciting is the recognition that genomic testing can and should be moved up in certain high-risk patients so more effective and targeted therapy can be applied earlier in the disease state. PMID: 31629413 [PubMed - in process]
Source: Canadian Journal of Urology - Category: Urology & Nephrology Tags: Can J Urol Source Type: research